TORC vs. SAVA, CLYM, MCRB, ANRO, XBIT, IVA, RENB, ENTA, NVCT, and MIST
Should you be buying resTORbio stock or one of its competitors? The main competitors of resTORbio include Cassava Sciences (SAVA), Climb Bio (CLYM), Seres Therapeutics (MCRB), Alto Neuroscience (ANRO), XBiotech (XBIT), Inventiva (IVA), Renovaro (RENB), Enanta Pharmaceuticals (ENTA), Nuvectis Pharma (NVCT), and Milestone Pharmaceuticals (MIST). These companies are all part of the "medical" sector.
resTORbio vs.
resTORbio (NASDAQ:TORC) and Cassava Sciences (NASDAQ:SAVA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.
resTORbio received 43 more outperform votes than Cassava Sciences when rated by MarketBeat users. Likewise, 67.14% of users gave resTORbio an outperform vote while only 65.33% of users gave Cassava Sciences an outperform vote.
Cassava Sciences is trading at a lower price-to-earnings ratio than resTORbio, indicating that it is currently the more affordable of the two stocks.
Cassava Sciences has a consensus target price of $111.50, indicating a potential upside of 4,307.11%. Given Cassava Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Cassava Sciences is more favorable than resTORbio.
In the previous week, Cassava Sciences had 23 more articles in the media than resTORbio. MarketBeat recorded 23 mentions for Cassava Sciences and 0 mentions for resTORbio. Cassava Sciences' average media sentiment score of 0.01 beat resTORbio's score of 0.00 indicating that Cassava Sciences is being referred to more favorably in the news media.
46.2% of resTORbio shares are owned by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are owned by institutional investors. 11.8% of resTORbio shares are owned by insiders. Comparatively, 9.0% of Cassava Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
resTORbio has a beta of 2.43, indicating that its share price is 143% more volatile than the S&P 500. Comparatively, Cassava Sciences has a beta of -0.99, indicating that its share price is 199% less volatile than the S&P 500.
resTORbio's return on equity of -78.12% beat Cassava Sciences' return on equity.
Summary
resTORbio beats Cassava Sciences on 8 of the 15 factors compared between the two stocks.
Get resTORbio News Delivered to You Automatically
Sign up to receive the latest news and ratings for TORC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
resTORbio Competitors List
Related Companies and Tools
This page (NASDAQ:TORC) was last updated on 1/23/2025 by MarketBeat.com Staff